Bogart Wealth LLC Increases Position in Edwards Lifesciences Co. (NYSE:EW)

Bogart Wealth LLC boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 38.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,768 shares of the medical research company’s stock after purchasing an additional 25,657 shares during the period. Bogart Wealth LLC’s holdings in Edwards Lifesciences were worth $6,868,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of EW. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences in the fourth quarter worth about $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences in the third quarter valued at about $32,000. Avior Wealth Management LLC raised its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Finally, JFS Wealth Advisors LLC lifted its holdings in Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on EW. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday. Barclays raised their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Truist Financial reissued a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Up 0.2 %

Edwards Lifesciences stock opened at $75.96 on Friday. The company’s 50-day moving average price is $72.51 and its two-hundred day moving average price is $69.36. The stock has a market cap of $44.80 billion, a price-to-earnings ratio of 10.96, a PEG ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. The trade was a 12.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,750 shares of company stock worth $1,564,255 over the last 90 days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.